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Abstract 
The burden of hepatitis C infection is considerable among people who inject drugs (PWID), 
with an estimated prevalence of greater than 40%, representing an estimated 5.6 million 
people who have recently injected drugs living with hepatitis C infection. As such, PWID are 
a priority population for enhancing prevention, testing, linkage to care, treatment and follow-
up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 
2030. There are many barriers to enhancing hepatitis C prevention and care among PWID 
including; poor global coverage of harm reduction services, restrictive drug policies and 
criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to 
care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies 
and government investment to support WHO elimination goals. On 5 September 2017, the 
International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of 
international experts to discuss remaining challenges and future priorities for action from a 
health systems perspective. The WHO health systems framework comprises six core 
components; service delivery, health workforce, health information systems, medical 
procurement, health systems financing, and leadership and governance. Communication has 
been proposed as a seventh key element which promotes the central role of affected 
community engagement. This review paper presents recommended strategies for eliminating 
hepatitis C as a major public health threat among PWID and outlines future priorities for 
action within a health systems framework. 
Key words: elimination; health systems; people who inject drugs; viral hepatitis C 
 
 
 
 
Key Points:  
• PWID are a priority population in efforts to eliminate hepatitis C globally  
• There are many interventions effective for hepatitis C prevention, linkage to testing, 
care, and treatment in PWID  
• Future efforts to eliminate hepatitis C among PWID requires interventions across 
the six core components of a health systems framework including: service delivery, 
health workforce, health information systems, medical procurement, health systems 
financing, and leadership and governance 
• Communication is a key component of the hepatitis C elimination response, 
promoting the central role of community engagement and ensuring dynamic 
interaction among the six traditional building blocks 
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Introduction 
Hepatitis B and hepatitis C account for approximately 1.34 million deaths globally, 
surpassing all chronic infectious diseases including HIV, malaria and tuberculosis
4
. It is 
estimated that 71 million people are living with chronic hepatitis C infection
5
.  The burden of 
hepatitis C-related morbidity and mortality continues to rise
4,6
. However, broad access to 
direct-acting antiviral (DAA) hepatitis C regimens with cure rates of over 95%
7
, provides an 
opportunity to reverse the rising burden of liver disease attributable to hepatitis C infection.  
 
The burden of hepatitis C infection is considerable among people who inject drugs (PWID), 
with an estimated prevalence of greater than 40%, representing an estimated 6.1 million 
people who have recently injected drugs living with hepatitis C infection (9% of all infections 
globally)
5,8,9
. There is also considerable heterogeneity in the burden of hepatitis C infection 
among people who have recently injected drugs (Figure 1), with half of infections from just 
four countries: the Russian Federation, the United States, China, and Brazil
9
. PWID are a 
priority population for enhancing prevention, testing, linkage to care, treatment and follow-up 
care. 
 
In 2016, the World Health Organization (WHO) set an ambitious goal to eliminate hepatitis C 
as a major public health threat by 2030. Specific targets include increasing sterile 
needles/syringes distributed from 20 to 200 per person per year for PWID, reducing new 
hepatitis C infections by 80%, and hepatitis C -related deaths by 65%, and increasing 
hepatitis C diagnoses from <20% to 90%, and the number of people receiving hepatitis C 
treatment from <10% to 80%
10,11
. 
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There are many barriers to enhancing hepatitis C prevention, diagnosis, linkage to care and 
treatment to achieve the WHO targets among PWID. Challenges include poor global 
coverage of harm reduction services, restrictive drug policies and criminalization of drug use, 
poor access to health services, low hepatitis C testing, linkage to care and treatment, 
restrictions for accessing DAA therapy, and the lack of national strategies and government 
investment to support WHO elimination goals
7,12
. 
 
However, recent advances in the simplification of hepatitis C testing, diagnosis and treatment 
present an opportunity to enhance hepatitis C care among PWID. On 5 September 2017, prior 
to the 6
th
 International Symposium on Hepatitis in Substance Users (INHSU 2017), the 
International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of 
international experts in drug and alcohol, infectious diseases, and hepatology to discuss 
remaining challenges and future priorities for action from a health systems perspective. 
Concepts and priorities were further developed through subsequent consultation. This paper 
presents recommended actions based on the expert input from the roundtable, follow-up 
consultation and evidence from the literature. It highlights the available scientific evidence 
regarding strategies to enhance hepatitis C prevention, testing, linkage to care, and treatment 
for PWID and outlines future priorities for action within a health systems framework. 
 
Interventions to enhance hepatitis C prevention, testing and treatment to achieve hepatitis 
C elimination among people who inject drugs 
Hepatitis C prevention  
In 2015, there were an estimated 1.7 million new hepatitis C infections globally, with 23% 
occurring among people who inject drugs as a result of sharing of non-sterile injecting 
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equipment
11
, highlighting the elevated hepatitis C incidence among PWID in many settings
13-
16
, particularly in the initial years of injecting
14,17
. 
 
There is evidence of the effectiveness of combined opioid substitution therapy (OST) and 
high-coverage needle and syringe programmes (NSP) on reducing the risk of hepatitis C 
acquisition in PWID
14,15
. OST is associated with a 50% reduction in hepatitis C acquisition 
risk, while combined OST and NSP are associated with a 74% reduction in hepatitis C 
transmissions
18
. NSP are also recognized as one of the most cost-effective public health 
interventions
19
. NSP and OST also have many other social, health and economic benefits 
beyond hepatitis C prevention, including prevention of HIV transmission and reducing death 
from overdose
20-22
. 
 
Increasing hepatitis C treatment among PWID also has potential prevention benefits and is 
cost-effective
23-25
. As per international guidelines, given PWID are at a high risk of hepatitis 
C transmission, and hepatitis C treatment resulting in cure eliminates infectiousness which 
may yield transmission reduction benefits, PWID are a high priority for treatment
26-29
.  
 
However, mathematical modelling studies suggest that whilst hepatitis C treatment for PWID 
can lead to substantial reductions in hepatitis C prevalence and reduce transmission
30-34
, 
prevention benefits are greatest when delivered in combination with OST and NSP
31,35,36
. 
Similarly, theoretical modelling indicates that whilst harm reduction has likely averted high 
HCV prevalence in some settings, scale-up of OST and NSP alone is unlikely to achieve 
WHO elimination incidence targets
31,37
. Therefore, a combination prevention strategy 
including hepatitis C treatment as prevention and increased coverage of harm reduction 
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interventions is critical for achieving reductions in hepatitis C prevalence/incidence among 
PWID
23
.  
 
Hepatitis C testing 
Globally, hepatitis C testing and diagnosis remains inadequate, both in terms of numbers 
(<20% diagnosed) and completeness of tests offered (even fewer have been HCV RNA 
tested), in particular for PWID
38-41
. In a systematic review of the effectiveness of 
interventions to improve hepatitis C testing among PWID, on-site testing with pre-test 
discussion and education and dried blood spot (DBS) testing were demonstrated to be 
effective in increasing hepatitis C testing among PWID when compared to control 
interventions
42
. Other strategies that have been evaluated (without any comparator 
intervention) include physical and electronic medical chart reminders to prompt targeted risk-
based assessment and testing
43-47
, peer-delivered outreach hepatitis C testing and hepatitis C 
education
48
, prison-based outreach testing
49
, patient referral contact tracing with monetary 
incentive for testing
50
, and point-of-care hepatitis C testing
51-57
. Decisions on what 
intervention(s) to implement to enhance hepatitis C testing will depend on the setting (and 
prevalence of hepatitis C infection), the model of care, the local context, and healthcare 
system. Decisions should also be based on engagement with the affected community to assess 
what testing interventions are most appropriate. Interventions should be implemented in a 
way that is respectful of individual choice and priorities. There is a lack of quality evidence 
on the most effective testing strategies, as such, strategies should be trialed and implemented 
in a way that is consultative and responsive rather than prescriptive.  
 
Linkage to hepatitis C care and treatment 
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Linkage of PWID to hepatitis C care and treatment is insufficient internationally
38-40
. In a 
systematic review of studies to improve linkage to hepatitis C care for PWID in the 
interferon-era, facilitated referral (either a nurse, peer-support worker or patient navigator) 
for hepatitis C assessment and scheduling of specialist appointments was associated with 
improved linkage to hepatitis C care
42
. Integrated hepatitis C care within drug use and 
psychiatric services delivered by a multidisciplinary team with case management services, 
with or without non-invasive liver disease assessment, was associated with improved 
hepatitis C treatment uptake
42
. Other strategies evaluated and shown to enhance hepatitis C 
linkage to care and treatment include dried blood spot testing
58
, point-of-care hepatitis C 
testing
54,55
, non-invasive liver disease screening using transient elastography (FibroScan
®
) 
with facilitated referral to care
59-61
, integrated hepatitis C care
43,62-66
, patient navigation 
programs
67,68
, peer-based support
69-81
, financial incentive programs
82,83
, and telemedicine
84-87
. 
However, the majority of interventions that have been evaluated are specific for the 
interferon-era. Further research is needed to evaluate optimal interventions for linkage to 
hepatitis C care and treatment with interferon-free DAA therapy. Similar to efforts to increase 
hepatitis C testing, decisions on what intervention(s) to implement to enhance hepatitis C 
linkage to care and treatment will depend on the setting and prevalence of hepatitis C 
infection, the model of care, and the local context and healthcare system (which includes who 
can prescribe therapy and the reimbursement restrictions in place).   
 
Models of hepatitis C care 
There is evidence that different models of care are effective for linkage of PWID to hepatitis 
C care and treatment including in hospital-based specialist clinics, community health centers, 
drug treatment clinics, prisons, NSP, supervised consumption rooms, and primary care
88
. The 
common theme from this spectrum of hepatitis C care models is that “one size does not fit 
Page 10 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
10 
 
all”
88
. Models of care which provide on-site hepatitis C care in venues where PWID are 
already accessing services are important
88
. With the availability of simple DAA therapies, the 
expansion of hepatitis C care to primary care, prisons, and other non-hospital settings, as well 
as broadening the types of health care professionals providing care, will greatly enhance 
access to hepatitis C care and treatment for PWID.    
 
Hepatitis C treatment 
DAA therapy has improved the feasibility of hepatitis C treatment among PWID compared to 
interferon-based therapies, given DAA therapies have limited psychiatric side-effects, are 
simpler (oral, once-daily vs. weekly injections), and shorter in duration (8-12 weeks vs. 24-48 
weeks). DAA therapy is effective among PWID receiving OST
89-99
, people with a history of 
injecting drug use
82,100-105
, and recent PWID
99,106-108
, including those with hepatitis C/HIV co-
infection
93-95,101,104,105,109
. There is no impact of drug use prior to or during treatment on 
response to DAA therapy among people receiving OST
98,99
 or people with recent injecting 
drug use
99,108
. Concomitant alcohol use also has no impact on DAA treatment outcomes
110
. 
Hepatitis C reinfection incidence among PWID is 0.0-5.3/100 person-years
111-118
, with higher 
rates among those with ongoing injecting (4.9-6.4/100 person-year)
112,114,115,117
. Strategies to 
enhance hepatitis C prevention, such as access to high-coverage NSP and OST (>200 needle-
syringes distributed per PWID and >40 OST recipients per 100 PWID) are crucial to 
minimize hepatitis C reinfection risk.  
 
Remaining challenges and key recommendations for action from a health systems 
perspective to achieve hepatitis C elimination among people who inject drugs 
 
Health Systems Building Blocks 
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A health system, as defined by WHO is all the organizations, institutions, resources and 
people whose primary purpose is to improve health
1,2
.  The WHO health systems framework 
comprises six core components, some of which underpin other components, such as 
leadership/governance and health information systems, others are input components to the 
health system (financing and the health workforce), or reflect the outputs of the health system 
(medical products and technologies and service delivery)
1,2
. Communication has been 
proposed as a seventh key element. This promotes the central role of communication in the 
context of affected community engagement and ensures dynamic interaction among the six 
traditional building blocks
1,2
.   
 
Given the interdependent nature of health system components, barriers to hepatitis C care and 
treatment should be systematically addressed across all elements of the health systems 
framework to support sustainable improvement throughout the care cascade (Figure 2).  
 
Communication and Engagement  
A people-centered approach to the health systems framework promotes health care that is 
respectful of, and responsive to, the preferences, needs and values of affected communities. If 
communication and engagement is established as essential to the health systems framework 
this component provides a central tenet on which health strategies can be structured. As 
people who are actively involved in their own health care tend to have better outcomes
119
, 
there is potential to move beyond inefficient and inequitable health systems by focusing on 
patient participation and community-led health interventions. 
 
Key actions to enhance hepatitis C care for PWID through communication and patient 
engagement include:   
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1) Enhancing health care worker communication through education on stigmatizing 
language/terminology, attitudes, practices and policies; 
2) Providing peer-led hepatitis C, health promotion and health literacy education through 
drug user organisations; 
3) Facilitating consumer participation in hepatitis service design and delivery; 
4) Facilitating patient engagement in hepatitis C communication strategies; 
5) Ensuring patient representation on national hepatitis C strategy planning 
committees/reference groups. 
 
Service Delivery   
Service delivery is the provision of healthcare to people. All inputs to the health system, for 
example health workforce, medical procurement and health information systems are intended 
to enhance service delivery. WHO categorises good service delivery as possessing the 
following key characteristics: comprehensiveness, accessibility, coverage, continuity, quality, 
person-centeredness, coordination, and accountability and efficiency
1
. 
 
As previously mentioned, there are many effective models of hepatitis C service delivery 
shown to successfully link PWID to care and treatment, all of which require contextual 
considerations such as individual diversity and culture. The same considerations need to be 
applied to pro-active testing outreach campaigns for those individuals not connected to any 
healthcare services. 
 
New DAA therapies have simplified on-treatment monitoring and the resulting hepatitis C 
care pathway. This has increased the number of settings where hepatitis C services can be 
provided and has enabled a broader range of practitioners to be involved in prescribing (drug 
Page 13 of 33 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
13 
 
and alcohol specialists, general practitioners, pharmacists, nurses, and physician assistants) 
and supporting people through testing and care. This simplification has led to a wide 
spectrum of models of care that can improve hepatitis C service delivery.  
 
Key actions to enhance hepatitis C service delivery include: 
1) Establishing and supporting hepatitis C testing methodologies that do not require 
venepuncture (e.g. finger-stick and saliva) to enhance hepatitis C diagnosis, linkage to 
care, and treatment in a variety of settings;  
2) Supporting the concept of task-shifting towards the continued expansion of available 
practitioners who can provide hepatitis C testing, linkage to care and treatment;  
3) Delivering services to PWID in a non-judgmental and non-stigmatizing way. 
 
Health Workforce 
The health workforce is defined as ‘all people engaged in actions whose primary intent is to 
enhance health
120
. WHO identifies human resources as clinical staff, as well as management 
and support staff, i.e. those who do not deliver services directly but are essential to the 
performance of health systems
1
. 
 
Given the ease and lower side-effect profile of DAA therapy, it is possible to increase 
hepatitis C treatment through simplified models of care across a range of settings
88
.  
Integrating hepatitis C care into new settings, for example drug and alcohol services, entails 
service delivery by a broader multidisciplinary health workforce not previously involved in 
hepatitis C management
42
. 
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Key actions to enhance hepatitis C care for PWID through strengthening the health workforce 
include: 
1) Addressing health workforce limitations through increased hepatitis C education. 
Education must be contextually and culturally appropriate and provided through 
flexible, blended learning i.e. online and face-face. Education should focus on 
capacity strengthening within health systems through ‘train the trainer’ models and 
include a key focus on providing non-stigmatizing care; 
2) Developing and expanding the peer workforce. Peer-based models of care receive a 
high level of patient acceptability and are an effective way of creating trust between 
services, healthcare p oviders and patients
69,121
. Health practitioner definitions should 
be expanded to include peer workers as valued members of the health workforce and 
peers should be supported through appropriate remuneration and professional 
support/supervision; 
3) Encouraging and driving leadership within the workforce e.g. by reaching out to 
professional groups to create champions in various relevant disciplines. 
 
Health Information Systems 
Health information systems are the foundation of decision-making across the health system. 
They enable decision-makers to identify problems and needs, make evidence-based decisions 
on health policy, and allocate resources optimally
122
.  
 
Despite epidemiological estimates relating to hepatitis C prevalence and burden of disease 
within PWID, there are still gaps in research and monitoring data. Addressing evidence gaps 
and improving methods for data collection is a priority for meeting global hepatitis C 
elimination goals
12
.  
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Key actions to enhance hepatitis C care for PWID through health information systems 
include: 
1) Developing systems to enable electronic health medical record alerts to enhance 
hepatitis C testing in people at-risk who have not previously been tested or require 
ongoing risk-based testing; 
2) Assisting clients to understand how their data will be used and how their privacy will 
be protected; 
3) Collecting minimum program information at the outset of hepatitis C treatment scale-
up that can monitor the uptake of hepatitis C case-finding among PWID, including the 
number and proportion that enter hepatitis C treatment programs; 
4) Creating a hepatitis C treatment registry with linkage between laboratories and 
community hepatitis C treatment providers; 
5) Developing more efficient/flexible digital means of capturing data on hepatitis C 
testing and treatment among PWID (particularly in settings where no registry exists or 
can be established); 
6) Evaluating the impact of DAA treatment on hepatitis C-related morbidity and 
mortality, including hepatitis C prevalence and incidence, incidence of liver cancer 
and advanced liver disease (e.g. decompensated cirrhosis), and death among PWID. 
 
It is noted that as less restrictive care pathways are enabled through point-of-care testing and 
treatment access in community settings, it may become more challenging to establish or 
maintain classical disease registries. This reinforces the need to create alternative, digital 
means of capturing data. 
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Medical Procurement  
According to WHO, a well-functioning health system ensures equitable access to essential 
medical products and technologies of assured quality, safety, efficacy and cost-
effectiveness
123
.  
 
The availability of new hepatitis C diagnostics that are highly sensitive, quick and 
inexpensive, has facilitated the simplification of hepatitis C testing
124-129
. DAA therapies have 
also dramatically simplified on-treatment monitoring needs
124
. 
 
Point-of-care and DBS testing have been shown to increase uptake of hepatitis C 
testing
42,47,54-56,130
 and linkage to hepatitis C care
54,55,58
. Both have the potential to reduce non-
attendance to off-site phlebotomy and provide more immediate results to facilitate enhanced 
education and linkage to care. This is particularly useful for remote/rural and outreach 
settings. 
 
Point-of-care hepatitis C testing can include oral fluid rapid diagnostic testing
125-129
, finger-
stick whole-blood rapid diagnostic testing
126-129,131,132
, on-site venepuncture-based 
testing
133,134
, and finger-stick capillary whole blood testing
57
. Although DBS testing is not 
strictly point-of-care, the ability to collect a finger-stick sample at the point-of-care simplifies 
sample collection, transportation to the laboratory, and diagnosis
130,135-137
.  
 
Key actions to enhance hepatitis C care for PWID through medical procurement include:  
1) Simplifying, and disinvesting from, existing clinical algorithms for testing and 
treatment, ensuring a focus on improvement engagement with PWID; 
Page 17 of 33 Liver International
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2) Increasing certification of currently available diagnostics – particularly those that do 
not require a venous blood draw - e.g. oral tests, finger-stick blood tests – to increase 
access to testing for PWID; 
3) Developing and certifying affordable diagnostics – particularly those that focus on 
community-based testing and reduce phlebotomy – to increase access to testing for 
PWID. 
 
Health Systems Financing  
Health financing is fundamental to the functionality of the health system. It involves both 
revenue generation/collection and purchasing/provision of services. Optimal health care 
financing allows access to needed services through efficient resource utilization.  
 
The high cost of hepatitis C treatment continues to be a topic of concern; however, given 
economic and population prevention benefits, scaling up hepatitis C treatment and care in 
PWID has been shown to be cost-effective despite high drug costs and risk of reinfection
23-25
.  
 
Globally, there is a lack of transparency in hepatitis c treatment financing mechanisms. 
Greater clarity and sharing of funding mechanisms would allow for a greater coordinated and 
effective global response.  
 
Exploring new funding mechanisms and ensuring the financial sustainability of hepatitis C 
prevention and treatment programs should be an important focus for all health systems. 
 
Key actions for enhancing hepatitis C care through financing include: 
1) Identifying models of hepatitis C elimination success in settings with different 
economic health system structures and epidemic characteristics; 
Page 18 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
18 
 
2) Advocating for transparent sharing of successes in drug procurement and pricing; 
3) Developing investment cases including budgetary impact, epidemic impact (general 
and among PWID), cost-effectiveness and optimal resource allocation strategies 
ensuring equity. 
 
Leadership and Governance  
Effective health system leadership and governance enables strategic policy frameworks, 
effective service delivery oversight, coalition-building, regulation, attention to system design 
and accountability
123
. As a cross-cutting component of the health systems framework, 
leadership and governance is an integral part of improving health outcomes. 
 
In the context of eliminating hepatitis C, although “early adopter” countries, and regions / 
sites within countries, many of whom have developed national strategies, action plans and 
clinical guidelines, are showing that rapid scale up of testing and treatment can be achieved 
through committed political leadership
11
, not all areas have such governance guidelines. To 
meet elimination targets by 2030 a comprehensive and global public health approach is 
needed.   
 
Key actions for enhancing hepatitis C prevention and care through leadership and governance 
include: 
1) Encouraging all countries to develop a national strategy with an action plan; 
2) Ensuring engagement of key affected populations, preferably through leadership 
roles, in the development of national strategies and action plans; 
3) Developing treatment guidelines specifically noting that PWID should not be 
excluded from treatment and addressing primary prevention to prevent reinfection; 
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4) Ensuring a financial commitment from national and regional/state governments; 
5) Identifying what scale-up of harm reduction interventions are required to support 
hepatitis C treatment as prevention strategy; 
6) Developing mechanisms for monitoring and evaluation to be able to provide data on 
whether progress is being made; 
7) Identifying champions to drive change – from the community, clinicians, public 
health and government. 
 
Conclusion  
People who inject drugs, one of the populations most affected by hepatitis C, should be a 
priority population for interventions to prevent and treat the infection. If hepatitis C 
elimination is to be achieved a people-centered health systems approach is required, 
providing a framework for action in which PWID are engaged in all components of their care, 
from diagnosis to treatment and follow-up care. At present, this is seldom the case. This 
paper presents a series of recommendations, based on expert opinion and published evidence, 
for how to improve care for PWID in each of the WHO six health systems buildings blocks. 
The seventh central component - ensuring adequate communication among the different parts 
of the health system and the PWID population - is put forth as a core element of the hepatitis 
C elimination response. 
 
REFERENCES 
1. WHO. Monitoring the building blocks of health systems: a handbook of indicators 
and their measurement strategies. Geneva, Switzerland.2010. 
2. WHO. Everybody business : strengthening health systems to improve health 
outcomes : WHO’s framework for action. Geneva, Switzerland2007. 
Page 20 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
20 
 
3. Lazarus JV, France T. A new era for the WHO health system building blocks? 2014; 
http://www.healthsystemsglobal.org/blog/9/A-new-era-for-the-WHO-health-
system-building-blocks-.html. Accessed June 30, 2018, 2018. 
4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 
1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 
2016;388(10049):1081-1088. 
5. The Polaris Observatory HCV Collaborators. Global prevalence and genotype 
distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastro 
Hepatol. 2017;2(3):161-176. 
6. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. 
Nature Reviews in Gastroenterology & Hepatology. 2013;10(9):553-562. 
7. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. 
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic 
Review. Annals of internal medicine. 2017;166(9):637-648. 
8. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use 
and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in 
people who inject drugs: a multistage systematic review. Lancet Global Health. 
2017;5(12):e1192-e1207. 
9. Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of 
hepatitis C infection among people who have recently injected drugs. Addiction. 
2018. 
10. WHO. Global health sector strat gy on viral hepatitis 2016-2021. 2017; 
http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-
eng.pdf?ua=1. Accessed June 5, 2017. 
11. WHO. Global Hepatitis Report 2017. . Geneva: World Health Organization;2017. 
12. Grebely J, Bruneau J, Lazarus JV, et al. Research priorities to achieve universal access 
to hepatitis C prevention, management and direct-acting antiviral treatment among 
people who inject drugs. The International journal on drug policy. 2017;47:51-60. 
13. Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among 
people who inject drugs in Europe: a systematic review of data for scaling up 
treatment and prevention. PloS one. 2014;9(7):e103345. 
14. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of 
hepatitis C virus infection in relation to time since onset of illicit drug injection: the 
influence of time and place. American journal of epidemiology. 2008;168(10):1099-
1109. 
15. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C 
virus infection in young adult injectors: using evidence to inform comprehensive 
prevention. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. 2013;57 Suppl 2:S32-38. 
16. Morris MD, Shiboski S, Bruneau J, et al. Geographic Differences in Temporal 
Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The 
InC3 Collaboration. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2017;64(7):860-869. 
17. Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-
involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009;102(1-
3):158-161. 
Page 21 of 33 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
21 
 
18. Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid 
substitution therapy for preventing HCV transmission among people who inject 
drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2017. 
19. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of 
harm reduction. The International journal on drug policy. 2015;26 Suppl 1:S5-11. 
20. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study 
on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 
2008;103(9):1484-1492. 
21. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of 
injecting opioid users for prevention of HIV infection. The Cochrane database of 
systematic reviews. 2011(8):CD004145. 
22. MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and 
Hepatitis C in people who inject drugs: a review of reviews to assess evidence of 
effectiveness. The International journal on drug policy. 2014;25(1):34-52. 
23. Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint 
for attaining excellence in health care and reducing premature mortality from 
lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 
2014;384(9958):1953-1997. 
24. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus 
antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49-
57. 
25. Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-
acting antiviral era: An economic evaluation. Journal of hepatology. 2016;65(1):17-
25. 
26. AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating 
Hepatitis C. 2017; https://www.hcvguidelines.org/. Accessed March 18, 2017. 
27. EASL. EASL Recommendations on Treatment of Hepatitis C 2016. Journal of 
hepatology. 2017;66(1):153-194. 
28. Grebely J, Robaeys G, Bruggmann P, et al. Recommendations for the management of 
hepatitis C virus infection among people who inject drugs. The International journal 
on drug policy. 2015;26(10):1028-1038. 
29. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C 
infection. Geneva, Switzerland2014. 
30. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can 
antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug 
user populations? A modeling analysis of its prevention utility. Journal of hepatology. 
2011;54(6):1137-1144. 
31. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination 
interventions to prevent HCV transmission among people who inject drugs: modeling 
the impact of antiviral treatment, needle and syringe programs, and opiate 
substitution therapy. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2013;57 Suppl 2:S39-45. 
32. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention 
among people who inject drugs: Modeling treatment scale-up in the age of direct-
acting antivirals. Hepatology. 2013;58(5):1598-1609. 
33. de Vos AS, Prins M, Kretzschmar ME. Hepatitis C Virus treatment as prevention 
among injecting drug users: who should we cure first? Addiction. 2015. 
Page 22 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
22 
 
34. Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on 
hepatitis C transmission and treatment in people who inject drugs. Hepatology. 
2014;60(6):1861-1870. 
35. Fraser H, Zibbell J, Hoerger T, et al. Scaling-up HCV prevention and treatment 
interventions in rural United States-model projections for tackling an increasing 
epidemic. Addiction. 2018;113(1):173-182. 
36. Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the 
impact of HCV treatment in the prevention of HCV transmission among people who 
inject drugs in Europe. Journal of hepatology. 2018;68(3):402-411. 
37. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes 
and opiate substitution therapy achieve substantial reductions in hepatitis C virus 
prevalence? Model projections for different epidemic settings. Addiction. 
2012;107(11):1984-1995. 
38. Saraswat V, Norris S, de Knegt RJ, et al. Historical epidemiology of hepatitis C virus 
(HCV) in select countries - volume 2. Journal of viral hepatitis. 2015;22 Suppl 1:6-25. 
39. Liakina V, Hamid S, Tanaka J, et al. Historical epidemiology of hepatitis C virus (HCV) 
in select countries - volume 3. Journal of viral hepatitis. 2015;22 Suppl 4:4-20. 
40. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus 
(HCV) in selected countries. Journal of viral hepatitis. 2014;21 Suppl 1:5-33. 
41. Lazarus JV, Sperle I, Spina A, Rockstroh JK. Are the testing needs of key European 
populations affected by hepatitis B and hepatitis C being addressed? A scoping 
review of testing studies in Europe. Croatian medical journal. 2016;57(5):442-456. 
42. Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to 
enhance testing, linkage to care and treatment uptake for hepatitis C virus infection 
among people who inject drugs: A systematic review. The International journal on 
drug policy.In Press. 
43. Zhou K, Fitzpatrick T, Walsh N, et al. Interventions to optimise the care continuum 
for chronic viral hepatitis: a systematic review and meta-analyses. The Lancet 
Infectious diseases. 2016. 
44. Krauskopf K, Kil N, Sofianou A, et al. Evaluation of an electronic health record prompt 
for hepatitis c antibody screening of baby boomers in primary care-a cluster 
randomized control trial. Journal of General Internal Medicine. 2014;29:S88-S89. 
45. Litwin AH, Smith BD, Drainoni ML, et al. Primary care-based interventions are 
associated with increases in hepatitis C virus testing for patients at risk. Digestive 
and liver disease : official journal of the Italian Society of Gastroenterology and the 
Italian Association for the Study of the Liver. 2012;44(6):497-503. 
46. Drainoni ML, Litwin AH, Smith BD, et al. Effectiveness of a risk screener in identifying 
hepatitis C virus in a primary care setting. American journal of public health. 
2012;102(11):e115-121. 
47. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based 
interventions to enhance assessment, treatment, and adherence in the chronic 
Hepatitis C care continuum. The International journal on drug policy. 
2015;26(10):922-935. 
48. Aitken CK, Kerger M, Crofts N. Peer-delivered hepatitis C testing and counselling: a 
means of improving the health of injecting drug users. Drug and alcohol review. 
2002;21(1):33-37. 
Page 23 of 33 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
23 
 
49. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison 
outreach clinic for the diagnosis and prevention of hepatitis C: Implications for the 
national strategy. Gut. 2003;52(10):1500-1504. 
50. Brewer DD, Hagan H. Evaluation of a patient referral contact tracing programme for 
hepatitis B and C virus infection in drug injectors. Eurosurveillance. 2009;14(14). 
51. Conway B, Vafadary S, Sharma S, et al. The community pop-up clinic as a tool of 
engagement for vulnerable populations with HCV and HIV infections. Journal of 
Hepatitis. 2015;2(1):1-4. 
52. Cosmaro ML, Oldrini M, Rancilio L, et al. Facilitated access procedures for HIV and 
HCV testing in vulnerable groups. Infection. 2011;39:S33. 
53. Remy AJ, Bouchkira H, Wenger H, Montabone S. News tools of screening viral 
hepatitis in real life: New french model of care. United European Gastroenterology 
Journal. 2015;1):A157. 
54. Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for 
hepatitis C testing and linkage to care for vulnerable populations: point-of-care and 
standard HCV testing in a mobile medical clinic. Journal of community health. 
2014;39(5):922-934. 
55. Bottero J, Boyd A, Gozlan J, et al. Simultaneous Human Immunodeficiency Virus-
Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: 
Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open 
forum infectious diseases. 2015;2(4):ofv162. 
56. Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus 
testing in the Rhode Island Department of Corrections. Journal of public health. 
2016;38(1):130-137. 
57. Grebely J, Lamoury FMJ, Hajarizadeh B, et al. Evaluation of the Xpert HCV Viral Load 
point-of-care assay from venepuncture-collected and finger-stick capillary whole-
blood samples: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(7):514-520. 
58. McAllister G, Innes H, McLeod A, et al. Uptake of hepatitis C specialist services and 
treatment following diagnosis by dried blood spot in Scotland. Journal of clinical 
virology : the official publication of the Pan American Society for Clinical Virology. 
2014;61(3):359-364. 
59. Moessner BK, Jorgensen TR, Skamling M, et al. Outreach screening of drug users for 
cirrhosis with transient elastography. Addiction. 2011;106(5):970-976. 
60. Foucher J, Reiller B, Jullien V, et al. FibroScan used in street-based outreach for drug 
users is useful for hepatitis C virus screening and management: a prospective study. 
Journal of viral hepatitis. 2009;16(2):121-131. 
61. Marshall AD, Micallef M, Erratt A, et al. Liver disease knowledge and acceptability of 
non-invasive liver fibrosis assessment among people who inject drugs in the drug 
and alcohol setting: The LiveRLife Study. The International journal on drug policy. 
2015;26(10):984-991. 
62. Cullen W, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among 
injecting drug users in general practice: a cluster randomised controlled trial of 
clinical guidelines' implementation. The British journal of general practice : the 
journal of the Royal College of General Practitioners. 2006;56(532):848-856. 
63. Masson CL, Delucchi KL, McKnight C, et al. A Randomized Trial of a Hepatitis Care 
Coordination Model in Methadone Maintenance Treatment. American journal of 
public health. 2013;103(10):E81-E88. 
Page 24 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
24 
 
64. Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated 
care intervention to increase eligibility for chronic hepatitis C treatment. The 
American journal of gastroenterology. 2011;106(10):1777-1786. 
65. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a 
chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. The 
American journal of gastroenterology. 2006;101(10):2254-2262. 
66. Ho SB, Brau N, Cheung R, et al. Integrated Care Increases Treatment and Improves 
Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness 
or Substance Abuse. Clinical gastroenterology and hepatology : the official clinical 
practice journal of the American Gastroenterological Association. 2015;13(11):2005-
2014 e2001-2003. 
67. Trooskin SB, Poceta J, Towey CM, et al. Results from a Geographically Focused, 
Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J 
Gen Intern Med. 2015;30(7):950-957. 
68. Falade-Nwulia O, Mehta SH, Lasola J, et al. Public health clinic-based hepatitis C 
testing and linkage to care in baltimore. Journal of viral hepatitis. 2016;23(5):366-
374. 
69. Crawford S, Bath N. Peer support models for people with a history of injecting drug 
use undertaking assessment and treatment for hepatitis C virus infection. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of 
America. 2013;57 Suppl 2:S75-79. 
70. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for 
hepatitis C virus infection in illicit drug users: a novel model incorporating 
multidisciplinary care and peer support. European journal of gastroenterology & 
hepatology. 2010;22(3):270-277. 
71. Norman J, Walsh NM, Mugavin J, et al. The acceptability and feasibility of peer 
worker support role in community based HCV treatment for injecting drug users. 
Harm Reduct J. 2008;5:8. 
72. Rance J, Treloar C. Integrating Treatment: Key findings from a qualitative evaluation 
of the Enhancing Treatment of Hepatitis C in Opiate Substitution Settings (ETHOS) 
study. Sydney: National Centre in HIV Social Research;2012. 
73. Musgrove SM. NUAA's ETHOS Projects: The Story of a Hep C Peer Support Worker & 
His Clinic. Paper presented at: 2nd International Symposium on Hepatitis in 
Substance Users2011; Brussels, Belgium. 
74. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve 
engagement and outcomes. The International journal on drug policy. 2007;18(5):406-
410. 
75. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent 
group treatment for hepatitis C: implementation and outcomes in a methadone 
maintenance treatment program. Journal of substance abuse treatment. 
2012;43(4):424-432. 
76. Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV 
antiviral treatment uptake among participants of a community-based HCV 
programme for marginalized patients. J Viral Hepat. 2012;19(12):836-842. 
77. Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. "It's easier to do 
stuff that's hard when you've got people to back you up:" description of a Hepatitis C 
Page 25 of 33 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
25 
 
Peer Education & Support Program in an opioid treatment program TBD. 2013;In 
Press. 
78. Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers 
to hepatitis C treatment among drug users: an integrated hepatitis C peer education 
and support program. Journal of health care for the poor and underserved. 
2014;25(2):652-662. 
79. Treloar C, Rance J, Bath N, et al. Evaluation of two community-controlled peer 
support services for assessment and treatment of hepatitis C virus infection in opioid 
substitution treatment clinics: The ETHOS study, Australia. Int J Drug Policy. 2015(In 
Press). 
80. Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus 
infection among people who inject drugs in the opiate substitution setting: the 
ETHOS study. Clin Infect Dis. 2013;In Press. 
81. Keats J, Micallef M, Grebely J, et al. Assessment and delivery of treatment for 
hepatitis C virus infection in an opioid substitution treatment clinic with integrated 
peer-based support in Newcastle, Australia. The International journal on drug policy. 
2015;26(10):999-1006. 
82. Sulkowski M, Ward K, Falade-Nwulia O, et al. Randomized controlled trial of cash 
incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV 
coinfected persons who inject drugs: the CHAMPS Study. Journal of hepatology. 
2017;66:S719. 
83. Norton BL, Singh R, Agyemang L, Litwin AH. Contingency Management Improves HCV 
Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot Study. Paper 
presented at: 5th International Symposum on Hepatitis Care in Substance Users 
(INHSU 2016)2016; Oslo, Norway. 
84. Mashru J, Kirlew M, Saginur R, Schreiber YS. Management of infectious diseases in 
remote northwestern Ontario with telemedicine videoconference consultations. 
Journal of telemedicine and telecare. 2017;23(1):83-87. 
85. Tahan V, Almashhrawi A, Kahveci AM, Mutrux R, Ibdah JA. Extension for Community 
Health Outcomes-hepatitis C: Small steps carve big footprints in the allocation of 
scarce resources for hepatitis C virus treatment to remote developing areas. World 
journal of hepatology. 2016;8(11):509-512. 
86. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus 
infection by primary care providers. The New England journal of medicine. 
2011;364(23):2199-2207. 
87. Lloyd AR, Clegg J, Lange J, et al. Safety and effectiveness of a nurse-led outreach 
program for assessment and treatment of chronic hepatitis C in the custodial setting. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society 
of America. 2013;56(8):1078-1084. 
88. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus 
among people who inject drugs: one size does not fit all. Clinical infectious diseases : 
an official publication of the Infectious Diseases Society of America. 2013;57 Suppl 
2:S56-61. 
89. Grebely J, Puoti M, Wedemeyer H, et al. Safety and Efficacy of Ombitasvir, 
Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepati ti s 
C Pati ents Receiving Opioid Substi tuti on Therapy: A Pooled Analysis Across 12 
Clinical Trials. Journal of hepatology. 2017;66:S514. 
Page 26 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
26 
 
90. Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and Safety of Sofosbuvir/Velpatasvir in 
Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution 
Therapy: Analysis of Phase 3 ASTRAL Trials. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America. 2016. 
91. Grebely J, Mauss S, Brown A, et al. Efficacy and Safety of Ledipasvir/Sofosbuvir With 
and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving 
Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America. 2016. 
92. Grebely J, Jacobson IM, Kayali Z, et al. SOF/VEL/VOX for 8 or 12 Weeks Is Well 
Tolerated and Results in High SVR12 Rates in Patients Receiving Opioid Substitution 
Therapy. Journal of hepatology. 2017;66:S513. 
93. Christensen S, Schober A, Mauss S, et al. DAA-Treatment of HCV-infected patients on 
Opioid Substitution Therapy (OST): does the clinical setting matter? Data from the 
German Hepatitis C-Registry (DHC-R). Hepatology. 2016;64(S1):982A-983A. 
94. Schutz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct Observed 
Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-
Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With 
Borderline Compliance Receiving Opioid Substitution Therapy. The American journal 
of gastroenterology. 2016;111(6):903-905. 
95. Scherz N, Brunner N, Bruggmann P. Direct-acting antivirals for hepatitis C in patient 
in opioid substitution treatment and heroin assisted treatment: real-life data. Journal 
of hepatology. 2017;66:S726. 
96. Dillon J, Mauss S, Nalpas C, et al. Efficacyand safety of Simeprevir-containing 
hepatitis C therapy in patients on opiate substitution therapy. Journal of hepatology. 
2017;66:S520. 
97. Boyle A, Marra F, Fox R, et al. Partial directly observed therapy with 
ombitasvir/paritaprevir based regimens allows for successful treatment of patients 
on daily supervised methadone. Journal of hepatology. 2017;66. 
98. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus 
Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals of 
internal medicine. 2016;165(9):625-634. 
99. Conway B, Grebely J, Fraser C, et al. Paritaprevir/ritonavir/ombitasvir, dasabuvir + 
ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving 
OST: The D3FEAT study. Paper presented at: 6th international Symposium on 
Hepatitis Care in Substance Users2017; New Jersey, United States. 
100. Norton BL, Fleming J, Steinman M, et al. High HCV Cure Rates for Drug Users Treated 
with DAAs at an Urban Primary Care Clinic. Paper presented at: Conference on 
Retroviruses and Opportunistic Infections; Feb 22-24 2016; Boston, United States. 
101. Conway B, Raycraft T, Bhutani Y, et al. Efficacy of All-Oral HCV Therapy in People 
Who Inject Drugs. Hepatology. 2016;64(S1):990A. 
102. Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-
based hepatitis C treatment for people who inject drugs: findings from the 
Queensland Injectors’ Health Network. The International journal on drug policy. 
2017;In Press. 
103. Mason K, Dodd Z, Guyton M, et al. Understanding Real-World Adherence in the 
Directly Acting Antiviral Era: a prospective evaluation of adherence amongst people 
Page 27 of 33 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
27 
 
with a history of drug use at a community-based program in Toronto, Canada. The 
International journal on drug policy. 2017;In Press. 
104. Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for 
hepatitis C to highly marginalised and current drug injecting populations in a 
targeted primary health care setting. The International journal on drug policy. 
2017;In Press. 
105. Litwin AH, Agyemang L, Akiyama M, et al. The PREVAIL Study: Intensive Models of 
HCV Care for People Who Inject Drugs Journal of hepatology. 2017;66:S72. 
106. Bouscaillou J, Kikvidze T, Butsashvili M, et al. Effectiveness of DAA-based treatment 
of HCV in active people who inject drugs living in middle income countries (MIC): the 
results of a prospective cohort study in Tbilisi, Georgia. Journal of hepatology. 
2017;66:S409. 
107. Boglione L, Mornese Pinna S, De Nicolo A, et al. Treatment with direct-acting 
antiviral agents of hepatitis C virus infection in injecting drug users: A prospective 
study. Journal of viral hepatitis. 2017. 
108. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus 
infection in people with recent injection drug use (SIMPLIFY): an open-label, single-
arm, phase 4, multicentre trial. Lancet Gastro Hepatol. 2018;In Press. 
109. Dore GJ, Altice F, Litwin AH, et al. Elbasvir/Grazoprevir to Treat HCV Infection in 
Persons Receiving Opioid Agonist Therapy: A Randomized Controlled Trial (C-EDGE 
CO-STAR). Annals of internal medicine. 2016;In Press. 
110. Tsui JI, Williams EC, Green PK, B rry K, Su F, Ioannou GN. Alcohol use and hepatitis C 
virus treatment outcomes among patients receiving direct antiviral agents. Drug and 
alcohol dependence. 2016;169:101-109. 
111. Cunningham EB, Applegate TL, Lloyd A , Dore GJ, Grebely J. Mixed HCV infection and 
reinfection in people who inject drugs--impact on therapy. Nature reviews 
Gastroenterology & hepatology. 2015;12(4):218-230. 
112. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among 
people who are actively injecting drugs: a systematic review and meta-analysis. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society 
of America. 2013;57 Suppl 2:S80-89. 
113. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection 
With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic 
Review and Meta-analysis. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2016;62(6):683-694. 
114. Midgard H, Bjoro B, Maeland A, et al. Hepatitis C reinfection after sustained 
virological response. Journal of hepatology. 2016;64(5):1020-1026. 
115. Weir A, McLeod A, Innes H, et al. Hepatitis C reinfection following treatment induced 
viral clearance among people who have injected drugs. Drug and alcohol 
dependence. 2016;165:53-60. 
116. Pineda JA, Nunez-Torres R, Tellez F, et al. Hepatitis C virus reinfection after sustained 
virological response in HIV-infected patients with chronic hepatitis C. The Journal of 
infection. 2015;71(5):571-577. 
117. Young J, Rossi C, Gill J, et al. Risk factors for hepatitis C virus reinfection after 
sustained virologic response in patients co-infected with HIV. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America. 2017. 
Page 28 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
28 
 
118. Dore GJ, Grebely J, Altice F, et al. HCV reinfection and injecting risk behavior 
following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-
STAR Three Year Follow-up Study. Hepatology. 2016;64(S1):431A. 
119. Rifkin SB. Examining the links between community participation and health 
outcomes: a review of the literature. Health Policy Plan. 2014;29 Suppl 2:ii98-106. 
120. WHO. The world health report 2006: working together for health. 2018. 
121. Treloar C, Rance J, Bath N, et al. Evaluation of two community-controlled peer 
support services for assessment and treatment of hepatitis C virus infection in opioid 
substitution treatment clinics: The ETHOS study, Australia. The International journal 
on drug policy. 2015;26(10):992-998. 
122. WHO. Health Metrics Network. Framework and standards for country health 
information systems. . 2008. 
123. WHO. The world health report 2006 – working together for health. Geneva, 
Switzerland.2006. 
124. Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: 
in search of a single visit diagnosis. Expert Rev Mol Diagn. 2017;17(12):1109-1115. 
125. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of 
rapid hepatitis C screening with an oral swab for community-based organizations 
serving high-risk populations. Am J Public Health. 2011;101(11):2151-2155. 
126. Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. Field-
based performance of three pre-market rapid hepatitis C virus antibody assays in 
STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San 
Diego, CA. J Clin Virol. 2012;54(3):213-217. 
127. Smith BD, Teshale E, Jewett A, et al. Performance of premarket rapid hepatitis C virus 
antibody assays in 4 national human immunodeficiency virus behavioral surveillance 
system sites. Clin Infect Dis. 2011;53(8):780-786. 
128. Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for 
detection of antibodies to hepatitis C virus. J Infect Dis. 2011;204(6):825-831. 
129. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-
care screening tests for hepatitis C: a systematic review and meta-analysis. Annals of 
internal medicine. 2012;157(8):558-566. 
130. Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot 
analysis on the uptake of hepatitis C virus testing in high-risk populations: A 
systematic review of the literature. The International journal on drug policy. 
2015;26(11):1050-1055. 
131. Wong VW, Wong GL, Chim AM, et al. Targeted hepatitis C screening among ex-
injection drug users in the community. J Gastroenterol Hepatol. 2013. 
132. Poiteau L, Soulier A, Rosa I, et al. Performance of rapid diagnostic tests for the 
detection of antibodies to hepatitis C virus in whole blood collected on dried blood 
spots. Journal of viral hepatitis. 2016;23(5):399-401. 
133. McHugh MP, Wu AHB, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE. 
Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin 
Microbiol. 2017;55(5):1550-1556. 
134. Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point -of -care testing (POCT) in 
molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in 
diagnosing and monitoring of HCV infection. Journal of clinical virology : the official 
publication of the Pan American Society for Clinical Virology. 2017;88:46-51. 
Page 29 of 33 Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
29 
 
135. Chevaliez S, Poiteau L, Rosa I, et al. Prospective assessment of rapid diagnostic tests 
for the detection of antibodies to hepatitis C virus, a tool for improving access to 
care. Clin Microbiol Infect. 2016;22(5):459 e451-456. 
136. Soulier A, Poiteau L, Rosa I, et al. Dried Blood Spots: A Tool to Ensure Broad Access to 
Hepatitis C Screening, Diagnosis, and Treatment Monitoring. The Journal of infectious 
diseases. 2016;213(7):1087-1095. 
137. Greenman J, Roberts T, Cohn J, Messac L. Dried blood spot in the genotyping, 
quantification and storage of HCV RNA: a systematic literature review. Journal of 
viral hepatitis. 2015;22(4):353-361. 
 
  
Page 30 of 33Liver International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
30 
 
Figure 1. Estimated number of people with recent injecting drug use living with HCV 
viraemic infection, by country. This figure has been reproduced with permission from
9
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Figure 2. Proposed modified WHO Health Systems Framework for PWID. This figure 
has been modified from_ENREF_3_ENREF_3
3
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Figure 1. Estimated number of people with recent injecting drug use living with HCV viraemic infection, by 
country.  
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Figure 2. Proposed modified WHO Health Systems Framework for PWID.  
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